We have not investigated the influence of FGF1 on other components of the HR pathway, for example, MRE11 and RAD51, in the current study - but highlight this as an interesting area for future focus, as differential expression of both genes has also previously been associated with platinum drug chemosensitivity in various cancers [57, 58], with RAD51 particularly related to platinum drug resistance in ovarian cancer following the restoration of genomic integrity through secondary reversion mutations [59]. The gene discussed is FGF1; the disease is ovarian carcinoma.